DNTH - Company ID 0001690585
The table below shows Dianthus Therapeutics, Inc. /DE/'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $55.69M | $110.55M | $627.67M | $55.98M | $13.24M | $10.12M |
| Short-term investments | $782.10M | $776.26M | $483.59M | $346.63M | $244.15M | $253.11M |
| Receivables | $582.00K | $106.00K | $1.23M | $5.00M | $39.00K | $1.00M |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $856.04M |
| $897.54M |
| $1.12B |
| $413.82M |
| $263.61M |
| $271.00M |
| Property, plant & equipment | $749.00K | $418.00K | $274.00K | $185.00K | $207.00K | $191.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.28B | $1.21B | $1.25B | $577.45M | $326.08M | $348.58M |
| Accounts payable | $5.50M | $6.39M | $5.27M | $6.71M | $5.40M | $8.27M |
| Total current liabilities | $28.52M | $34.39M | $38.28M | $23.86M | $20.09M | $16.95M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $34.82M | $41.25M | $45.57M | $30.99M | $23.00M | $19.97M |
| Retained earnings | -$474.42M | -$427.78M | -$377.56M | -$272.30M | -$235.53M | -$203.90M |
| Total equity | $1.24B | $1.17B | $1.20B | $546.45M | $303.08M | $328.61M |